AZD0901 Compared With Investigator ' s Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Conditions: Gastric Cancer; Gastroesophageal Junction Cancer Interventions: Drug: AZD0901; Drug: AZD0901; Drug: Ramucirumab+ paclitaxel; Drug: Paclitaxel; Drug: Docetaxel; Drug: Irinotecan; Drug: TAS-102; Drug: Apatinib Sponsors: AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | AstraZeneca | Cancer | Cancer & Oncology | Docetaxel | Gastric (Stomach) Cancer | Gastroenterology | Research | Taxotere